

Full title: Challenges in Clinical Diagnosis of Clade I Mpox: Highlighting the Need for Enhanced Diagnostic Approaches

Short title: Challenges in Clinical Diagnosis of Clade I Mpox

Authors: Josephine Bourner¹, Esteban Garcia¹, Festus Mbrennga², Yap Boum II², Amy Paterson¹, Benjamin Jones¹, Piero Olliaro¹, Emmanuel Nakouné², Amanda Rojek¹

Affiliations:

¹ ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK

² Institut Pasteur de Bangui, Bangui, Central African Republic

Corresponding author : josephine.bourner@ndm.ox.ac.uk

Abstract

Background: Due to limited diagnostic capacity and availability of point-of-care tests, diagnosis of Clade I mpox in the regions most affected by the disease is usually on clinical grounds and may be complicated due to the similarity between mpox and varicella (chickenpox) lesions. Clinical assessment of lesions is also used for determining clinical progress and has been used to assess patient outcomes in clinical trials. However, there has been no investigation into whether clinicians can (i) identify Clade I mpox compared to other viral lesions (ii) differentiate between Clade I mpox lesion stages.

Methodology/Principle findings: The objective of this study was to evaluate inter-rater reliability and agreement between clinicians assessing lesions in patients with Clade I mpox. We presented clinicians with 17 images of Clade I mpox or varicella and asked them to independently indicate the most likely diagnosis – mpox or varicella – and to categorise the lesions according to their stage. When selecting the most likely diagnosis, accuracy varied across all images, the inter-rater reliability was poor ($\kappa = 0.223$; $z = 10.1$) and agreement was moderate ($P_o = 68\%$). When categorising lesions according to their type, if a single lesion type was present in the image, inter-rater reliability was moderate ($\kappa = 0.671$, $z = 40.6$) and agreement was good ($P_o = 78\%$), but when multiple lesion types were shown in an image, both inter-rater reliability ($\kappa = 0.153$, $z = 10.5$) and agreement ($P_o = 29\%$) decreased substantially.

Conclusions: This study demonstrates that there are presently limitations in using clinical assessment to diagnose Clade I mpox and evaluate lesion stage and treatment outcomes, which have an impact on clinical practice, public health and clinical trials. More robust indicators and tools are required to inform clinical, public-health, and research priorities, but these must be implementable in countries affected by mpox.

Author summary

Mpox is a zoonotic illness caused by the monkeypox virus (MPXV), for which there are two distinct sub-clades. Clade I is typically found in central Africa and is associated with worse patient outcomes than Clade II. Diagnosis of mpox is most commonly performed using PCR, but in settings with limited laboratory capacity diagnosis is usually performed on clinical grounds taking lesion presentation in to account. Lesion presentation is also used to assess patient outcomes in both clinical and research settings. However, there has been no investigation into whether clinicians can (i) identify Clade I mpox compared to other viral lesions (ii) differentiate between Clade I mpox lesion stages, which has important implications for clinical practice, research and public health. Our study, which presented 16 clinicians with 17 sets of images of Clade I mpox or varicella and asked them to i) provide the most likely diagnosis and ii) categorise the lesions in to their stages, demonstrates that there are presently limitations in using clinical assessment to diagnose Clade I mpox and evaluate lesion stage and treatment outcomes. Alternative methods and tools are therefore required that can be easily implemented in affected countries.

1 Introduction

2 Mpx is a zoonotic illness caused by the monkeypox virus (MPXV), for which there are two distinct
3 genetic sub-types, referred to as Clades. (1) Clade I mpx is found primarily in central Africa and is
4 associated with worse patient outcomes than Clade II, which is further divided into Clade IIa
5 (historically reported in west Africa) and Clade IIb, which caused a Public Health Emergency of
6 International Concern (PHEIC) in 2022. (1)

7 There is a growing epidemic of Clade I mpx in the Democratic Republic of the Congo (DRC) – with a
8 doubling in the number of cases over last year’s. (2) There are several concerning features to this
9 outbreak, including an expansion in geographical areas affected, new introduction to dense urban
10 populations (including Kinshasa, the capital city of DRC), and the first descriptions of sexual
11 transmission of this clade. Both the World Health Organization (WHO) and European Centre for
12 Disease Prevention and Control risk assessments (ECDC) highlight that improving awareness and
13 support for clinicians to diagnose cases is a key response priority. (2, 3) While Clade II mpx is rarely
14 fatal – 156 death out of over 91,000 cases reported outside Africa since May 2002 – , mortality
15 associated with Clade I mpx is 1-12% (1) and there have been 581 deaths reported out of over
16 12,500 cases in DRC since February 2023. (2)

17 However, diagnosis of mpx is difficult. Confirmation of mpx diagnosis is primarily by PCR, (4, 5)
18 but, concerningly, new evidence suggests that the Clade I-specific RT-PCR test recommended by the
19 US CDC is impacted due to genetic mutations in the virus causing this outbreak. (6) There are no
20 point-of-care or rapid diagnostic tests alternatives at present. Laboratory diagnosis is impacted by
21 operational challenges and limited laboratory capacity –in the present DRC epidemic, only 9% of
22 suspected mpx cases have been tested by PCR. (7)

23 Therefore, diagnosis of Clade I mpx in the regions most affected is usually on clinical grounds. This
24 is reported as difficult due to the similarity between mpx and varicella (chickenpox) lesions. Clinical

25 assessment of lesions is also used for determining clinical progress. Whether a lesion is ‘active’,
26 ‘inactive’ or ‘resolved’ is used for determination of infectivity and infection-prevention and control
27 requirements, decisions around whether to offer a patient access to potential treatments, and
28 declarations of cure. The assessment of lesions has in addition become the focal area of evaluation
29 in clinical trials. Several trials for Clade I and Clade II mpox use time to lesion resolution as the
30 primary endpoint to indicate treatment success. (8-12)

31 Despite the myriad uses of clinical diagnosis of Clade I mpox, there has been no investigation into
32 whether clinicians can (i) identify Clade I mpox compared to other viral lesions (ii) differentiate
33 between Clade I mpox lesion stages – although some suspected limitations of this endpoint have
34 already been identified. (13) A previous exercise undertaken by these authors on Clade IIb lesions
35 demonstrated only moderate agreement among different assessors. (14)

36 This study evaluates agreement between clinicians on a differential diagnosis between Clade I mpox
37 and varicella, and classification of lesion stages. Whether mpox Clade I lesions can be reliably
38 classified on clinical grounds has important implications both in the low-resource settings where the
39 virus circulates and in the event of spread to historically non-endemic regions – for decisions on
40 treatment, public health control, and for the robustness of clinical research.

41 Methods

42 The objective of this study was to evaluate inter-rater reliability and agreement between clinicians
43 assessing lesions in patients with Clade I mpox. Two focal areas of agreement and reliability were
44 evaluated: 1) differential diagnosis between Clade I mpox and varicella based on lesion presentation;
45 2) categorisation of lesion stages. The design, conduct and results of this study are reported
46 according to the Guidelines for Reporting Reliability and Agreement Studies (GRAAS). (15) Ethical
47 approval for this study was obtained from the University of Oxford Medical Science Interdivisional
48 Research Ethics Committee (R84355/RE001).

49 Participants

50 The participants in this study were clinicians who had experience treating and managing patients
51 with Clade I mpox.

52 Data collection

53 Using the RedCap survey tool (16, 17), participants were shown 17 sets of images of patients with
54 either Clade I mpox or varicella lesions confirmed by PCR. The anonymised images selected for use in
55 the survey were derived from the Institut Pasteur de Bangui clinical image library and showed
56 lesions of different stages and located on different areas of the body.

57 Based on the lesion presentation in the images, the participants were asked to independently
58 indicate the most likely diagnosis – mpox or varicella – and to categorise the lesions as being either
59 active, scabbed or resolved, or they had the option to state they were unable to classify the lesions.
60 Before starting the questionnaire, participants were shown the World Health Organisation's working
61 definition of each lesion stage. (18)

62 The survey also captured each clinician's country of practice, average number of patients they
63 manage with Clade I mpox in a year, and their self-rated confidence evaluating mpox lesions.
64 Confidence evaluating mpox lesions was assessed on an ordinal scale from one to ten, with one
65 representing no confidence and ten representing complete confidence.

66 The questionnaire used in this study can be found in **S1 – Appendix 1** and was provided in both
67 English and French.

68 Data analysis

69 All analyses completed in this study were conducted with the 'irr' package in R Statistical Software
70 (v4.3.2) (19) and validated using 'statsmodels' package in Python (v3.11.5) by two analysts.

71 Accuracy identifying mpox or varicella was evaluated using the percentage of raters selecting the
72 correct diagnosis for each image. Spearman's rank correlation coefficient (Spearman's ρ) was

73 employed to assess the relationship between experience—assessed by self-reported expertise and
74 the number of patients managed— and each evaluator's accuracy percentage. Spearman's method,
75 chosen for its suitability with small samples and ordinal data without assuming a normal distribution,
76 necessitates a cautious interpretation of results due to the reduced statistical power and potential
77 influence of noise and outliers inherent to limited datasets.

78 Inter-rater reliability was evaluated using Fleiss' kappa coefficient (κ) and inter-rater agreement was
79 evaluated using proportion of partial agreement (P_o), and proportion of exact agreement (P_{oe}). Partial
80 agreement refers to the agreement between any one of the participants' selections in a multiple-
81 choice answer and exact agreement refers to a complete match between participants' selections in a
82 multiple-choice answer.

83 Questions related to lesion classification assessed only the images in which the patient had a
84 confirmed diagnosis of mpox. The first analysis evaluates responses to the images where only a
85 single or homogenous lesions were present and for which the κ and P_{oe} are reported. The second
86 analysis evaluates responses to the images where multiple types of lesions (combinations of active,
87 scabbed and resolved) are present, for which the κ , the P_o the P_{oe} are reported.

88 Results

89 The questionnaire was sent to 38 potential participants in total, of whom 17 accessed the
90 questionnaire and completed the eligibility check. One respondent was not eligible to participate as
91 they were not directly involved in the clinical management of patients with Clade I mpox.

92 All 16 participants who started the questionnaire completed it in full. A summary of the participants'
93 country of work, confidence assessing an mpox lesion and number of mpox patients they have
94 personally managed is summarised in **Table 1**.

95

96 **Table 1 – Description of study participants**

| Country of work, n (%): | |
|---|-------------|
| Democratic Republic of Congo | 8 (50%) |
| Central African Republic | 2 (13%) |
| France | 2 (13%) |
| United Kingdom | 2 (13%) |
| Nigeria | 1 (6%) |
| Belgium | 1(6%) |
| Number of mpox patients the respondents has personally managed, n (%): | |
| <5 | 0 |
| 5-10 | 2 (13%) |
| 10-20 | 1 (6%) |
| 20-50 | 5 (31%) |
| >50 | 8 (50%) |
| Confidence assessing mpox lesions, median (IQR): | |
| Confidence score | 8 (7.5 - 8) |

97

98 **Diagnosis**

99 Accuracy selecting the most likely diagnosis between mpox and varicella based on lesion

100 presentation varied across all images, with between 25% and 100% of the respondents correctly

101 identifying the disease and a median = 75% (Q1: 62.5%, Q3: 93.75%). No correlation was detected

102 between accuracy and either self-rated confidence (Spearman’s $\rho = 0.3$) or experience (Spearman’s ρ

103 = 0.17) assessing lesions (**Table 2**).

104 **Table 2 – Correlation between raters’ diagnostic accuracy, self-rated confidence and experience**

105 **using Spearman’s correlation (ρ)**

| | Image | Self-rated confidence | Experience |
|-----------------------|-------|-----------------------|------------|
| Image | 1 | 0.3 | 0.168 |
| Self-rated confidence | 0.3 | 1 | -0.042 |
| Experience | 0.168 | -0.042 | 1 |

106

107 When asked to select the most likely diagnosis of the patient between varicella and mpox based on
108 the lesion presentation shown in the images, the inter-rater reliability was poor ($\kappa = 0.223$; $z = 10.1$)
109 and agreement was moderate ($P_o = 68\%$). (**Fig 1**)

110 **Fig 1. Dendrogram of the suspected diagnosis associated with the images based on lesion**
111 **presentation**

112 In addition to the reported results, in the supplementary appendices we show that there appears to
113 be improved diagnostic accuracy if a single lesion type is present in the image, compared to images
114 in which lesions appeared to be in multiple concurrent stages of evolution (**S2 – Appendix 2**). We did
115 not observe any relationship between diagnosis and accuracy (**S2 – Appendix 2**). However, our
116 sample size is too small to draw any generalisable conclusions.

117 Lesion classification

118 When a single lesion type was present in the image, inter-rater reliability was moderate ($\kappa = 0.671$, z
119 $= 40.6$) and agreement was good ($P_o = 78\%$) (**Table 3, Fig 2**).

120 **Fig 2. Dendrogram of the respondents' lesion assessments for which a single lesion type was**
121 **present in the image**

122 However, when multiple lesion types were shown in an image, both inter-rater reliability ($\kappa = 0.153$, z
123 $= 10.5$) and agreement ($P_o = 29\%$) decreased substantially. (**Table 3**)

124 Where partial agreement was assessed, inter-rater reliability was moderate ($\kappa = 0.447$, $z = 25.9$) and
125 agreement was good ($P_o = 73\%$). (**Fig 3**) (**Table 2**)

126 **Fig 3. Dendrogram of the respondents' lesion assessments for which multiple lesion types were**
127 **present in the image**

128

129 **Table 3 – Summary of inter-rater reliability and agreement results**

| Diagnosis of patients in images | Response selection formats | Lesion types present in image | Fleiss' kappa | Z score | Percentage of agreement | |
|---------------------------------|----------------------------|---------------------------------|---------------|---------|---------------------------------|--------|
| | | | | | Type | Result |
| Mpox & Varicella | Single choice | Single types and multiple types | 0.223 | 10.1 | Percentage of exact agreement | 67.745 |
| Mpox | Single choice | Single types | 0.671 | 40.6 | Percentage of exact agreement | 78.14 |
| Mpox | Multiple choice | Multiple types | 0.447 | 25.9 | Percentage of partial agreement | 73.18 |
| Mpox | Multiple choice | Multiple types | 0.153 | 10.5 | Percentage of exact agreement | 29.04 |

130

131 Discussion

132 This study demonstrates that there are presently limitations in using clinical assessment to diagnose

133 Clade I mpox and evaluate lesion stage and treatment outcomes.

134 We found moderate accuracy, poor reliability, and moderate agreement among clinicians deciding

135 between mpox and varicella diagnosis based on lesion presentation. In settings where laboratory

136 diagnosis is not available, or delayed, there is a risk that patients could be managed according to an

137 incorrect care pathway (e.g. provision of an incorrect antiviral). Misclassification of cases can have

138 implications for public health activities as varied as disease surveillance, allocation of vaccinations,

139 drug procurement, and reporting of notifiable diseases obligations. This has consequences also for

140 the evaluation of treatment effects, both in clinical practice and research, with incorrect or

141 inconsistent classification of outcomes.

142

143 We found that for classification of mpox lesion status there was moderate reliability and good
144 agreement if a single lesion type is present – although this may not be sufficient to state that there is
145 good agreement beyond chance (20, 21) – but it appears to be most challenging to obtain consistent
146 assessments when multiple lesion types are present. As lesions are unlikely to follow the same
147 evolution pattern over time, the poor reliability and agreement between clinicians when multiple
148 lesion types are present creates a substantial challenge. This includes clinical trials, which rely on a
149 single overall assessment of a patient’s lesion presentation at a specific timepoint to act as an
150 indicator of a patient’s overall outcome and response to treatment.

151 These findings occurred despite the self-rated confidence among the participants being high (IQR:
152 7.5-8). We found no correlation between confidence and experience defined according to the
153 number of patients with mpox the respondent had managed (Fig 4). Due to the sporadic and
154 widespread reporting of Clade I mpox across a large geographic area, it is possible that confidence,
155 and agreement among real-world clinicians, who may only occasionally manage a patient with mpox
156 or varicella, may be lower than reported in this study where we sampled a relatively expert group.

157 **Fig 4. Scatterplot of respondents’ self-rated confidence plotted against experience (measured**
158 **according to the number of patients managed)**

159 A parallel study found higher agreement and reliability among clinicians assessing Clade IIb mpox
160 lesions. (14) This may be due to differences in lesion presentation between the two diseases, with
161 Clade IIb lesions often being more localised and fewer than Clade I lesions. The surveys were not
162 combined due to the significant differences in clinical presentation between the clades, and that
163 clinical experience spanning both clades is limited to a very small number of highly-expert clinicians.

164 There is a continued requirement for resources (such as the WHO lesion assessment atlas) to assist
165 clinicians and clinical triallists working in low-resource environments to improve their assessments,
166 alongside support for improved diagnostic capacity. There is an urgent need to work to improve and
167 find other correlates of disease progression (e.g. how much PCR status reflects ongoing infectivity).

168 Considering the lack of correlation between clinician experience and their ability to diagnose Clade I
169 Mpox, this study underscores the potential of Artificial Intelligence (AI) and Machine Learning (ML)
170 in improving Mpox diagnosis, especially in resource-constrained settings where access to doctors
171 may be limited and initial assessments are often conducted by nurses or community health workers.
172 The application of AI and ML technologies, capable of capturing and analysing images, presents a
173 significant opportunity to enhance the diagnostic accuracy of clinicians and nurses in areas lacking
174 PCR testing facilities. This advancement is particularly crucial before the availability of rapid
175 diagnostic tests. Although these technologies have demonstrated their efficacy during the pandemic,
176 specifically with the Clade IIb variant of Mpox, data on their effectiveness with Clade I remain scarce.
177 By leveraging AI, we can aim to bridge the diagnostic gap, ensuring timely and accurate detection of
178 Mpox, even in the most challenging environments, thereby improving patient outcomes and
179 controlling the spread of the disease more effectively. (22, 23)

180 [Limitations](#)

181 This study included a relatively low number of participants, because few clinicians worldwide have
182 current or recent experience managing patients with Clade I mpox. The response rate was also
183 challenged by difficulty identifying and reaching clinicians who work in remote areas with limited
184 internet connection. Assessments made by visual inspection of images may not be reflective of all
185 the information used to make assessments in a clinical scenario (such as patient's descriptions of
186 evolution of lesions, associated characteristics such as pain). We used reliability and agreement for
187 assessment of mpox lesions (compared to accuracy) because there is no 'gold standard' classification
188 to which to compare. We did not provide images where there was mpox and varicella coinfection.

189 [Conclusion](#)

190 It is difficult for experienced clinicians to distinguish clade I mpox from varicella, and to reliably
191 assess disease stage for clade I mpox. More robust indicators and tools are required to inform

192 clinical, public-health, and research priorities, but these must be implementable in countries
193 affected by Mpox.

194 Acknowledgements

195 This work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome
196 [215091/Z/18/Z] and the Bill & Melinda Gates Foundation [OPP1209135]. For the purpose of Open
197 Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript
198 version arising from this submission.

199 References

- 200 1. Mitjà O, Ogoina D, Titanji BK, Galvan C, Muyembe JJ, Marks M, Orkin CM. Monkeypox.
201 Lancet. 2023;401(10370):60-74.
- 202 2. European Centre for Disease Prevention and Control. Implications for the EU/EEA of the
203 outbreak of mpox caused by Monkeypox virus clade I in the Democratic Republic of the Congo.
204 2023.
- 205 3. World Health Organisation. Mpox (monkeypox) - Democratic Republic of the Congo. 2023.
- 206 4. Petersen E, Kantele A, Koopmans M, Asogun D, Yinka-Ogunleye A, Ihekweazu C, Zumla A.
207 Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention. Infect Dis
208 Clin North Am. 2019;33(4):1027-43.
- 209 5. Zhou Y, Chen Z. Mpox: a review of laboratory detection techniques. Arch Virol.
210 2023;168(8):221.
- 211 6. Masirika LM, Udaheuka JC, Schuele L, Ndishimye P, Otani S, Mbiribindi JB, et al. Novel Clade I
212 genome sequences from the ongoing mpox virus outbreak of Kamituga in South Kivu province,
213 Democratic Republic of Congo. Virological. 2024.
- 214 7. World Health Organisation. Disease Outbreak News: Monkeypox – Democratic Republic of
215 Congo. 2023.
- 216 8. Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus
217 Disease (UNITY) [Internet]. clinicaltrials.gov. 2022. Available from:
218 <https://clinicaltrials.gov/study/NCT05597735?cond=mpox&rank=5#study-record-dates>.
- 219 9. Study of Tecovirimat for Human Monkeypox Virus (STOMP) [Internet]. clinicaltrials.gov.
220 2022. Available from: [https://clinicaltrials.gov/study/NCT05534984?cond=mpox&rank=6#study-](https://clinicaltrials.gov/study/NCT05534984?cond=mpox&rank=6#study-record-dates)
221 [record-dates](https://clinicaltrials.gov/study/NCT05534984?cond=mpox&rank=6#study-record-dates).
- 222 10. European Trial Into Mpox Infection (EPOXI) [Internet]. clinicaltrials.gov. 2023. Available from:
223 <https://clinicaltrials.gov/study/NCT06156566?cond=mpox&rank=8#study-record-dates>.
- 224 11. Tecovirimat for Treatment of Monkeypox Virus [Internet]. clinicaltrials.gov. 2022. Available
225 from: [https://clinicaltrials.gov/study/NCT05559099?term=palm%20007&rank=1#study-record-](https://clinicaltrials.gov/study/NCT05559099?term=palm%20007&rank=1#study-record-dates)
226 [dates](https://clinicaltrials.gov/study/NCT05559099?term=palm%20007&rank=1#study-record-dates).
- 227 12. Antiviral treatment with tecovirimat for patients managed at home with mpox [Internet].
228 ISRCTN. 2022. Available from:
229 [https://www.isrctn.com/ISRCTN17461766?q=tecovirimat&filters=&sort=&offset=1&totalResults=3&](https://www.isrctn.com/ISRCTN17461766?q=tecovirimat&filters=&sort=&offset=1&totalResults=3&page=1&pageSize=10)
230 [page=1&pageSize=10](https://www.isrctn.com/ISRCTN17461766?q=tecovirimat&filters=&sort=&offset=1&totalResults=3&page=1&pageSize=10).

- 231 13. Rojek A, Dunning J, Olliaro P. Monkeypox: how will we know if the treatments work? *Lancet*
232 *Infect Dis.* 2022;22(9):1269-70.
- 233 14. Jones B, Paterson A, AlKhoury N, Bourner J, Dunning J, Olliaro P, Rojek A. Variability in
234 clinical assessment of clade IIb mpox lesions. *International Journal of Infectious Diseases.*
235 2023;137:60-2.
- 236 15. Kottner J, Audige L, Brorson S, Donner A, Gajewski BJ, Hróbjartsson A, et al. Guidelines for
237 Reporting Reliability and Agreement Studies (GRRAS) were proposed. *International Journal of*
238 *Nursing Studies.* 2011;48(6):661-71.
- 239 16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
240 capture (REDCap)—A metadata-driven methodology and workflow process for providing
241 translational research informatics support. *Journal of Biomedical Informatics.* 2009;42(2):377-81.
- 242 17. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium:
243 Building an international community of software platform partners. *Journal of Biomedical*
244 *Informatics.* 2019;95:103208.
- 245 18. Atlas of mpox lesions: a tool for clinical researchers, 28 April 2023 [Internet]. 2023. Available
246 from: <https://pesquisa.bvsalud.org/portal/resource/pt/who-366569>.
- 247 19. R Core Team. R: A language and environment for statistical computing. R Foundation for
248 Statistical Computing, Vienna, Austria; 2018.
- 249 20. Altman DG. *Practical Statistics for Medical Research.* 1st edition ed: Chapman and Hall/CRC;
250 1990.
- 251 21. Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data.
252 *Biometrics.* 1977;33(1):159-74.
- 253 22. Nayak T, Chadaga K, Sampathila N, Mayrose H, Gokulkrishnan N, Bairy G M, et al. Deep
254 learning based detection of monkeypox virus using skin lesion images. *Medicine in Novel Technology*
255 *and Devices.* 2023;18:100243.
- 256 23. Chadaga K, Prabhu S, Sampathila N, Nireshwalya S, Katta SS, Tan RS, Acharya UR. Application
257 of Artificial Intelligence Techniques for Monkeypox: A Systematic Review. *Diagnostics (Basel).*
258 2023;13(5).

259 Supporting information

260 S1 Appendix 1 – Questionnaire

261 S2 Appendix 2 – Summary of question characteristics and accuracy score

262 S3 Appendix 3 – Full dataset

